Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature-Reference-Cited by-同舟云学术

Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature

Published:2014-08-13 Issue:6b Volume:114 Page:E120-E129
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Faisal Farzana A.¹,Sundi Debasish¹,Pierorazio Phillip M.¹,Ball Mark W.¹,Humphreys Elizabeth B.¹,Han Misop¹,Epstein Jonathan I.¹,Partin Alan W.¹,Carter H. Ballentine¹,Bivalacqua Trinity J.¹,Schaeffer Edward M.¹,Ross Ashley E.¹

Affiliation:

1. Brady Urological Institute; Johns Hopkins University; Baltimore MD USA

Funder

Johns Hopkins Clinician Scientist Award

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12771/fullpdf

Reference23 articles.

1. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer;D'Amico;JAMA,1998

2. Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer;Pierorazio;BJU Int,2011

3. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure;D'Amico;J Urol,2003

4. Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy;Walz;BJU Int,2010

5. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors;D'Amico;Cancer,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. LDR-Brachytherapy monotherapy appears unsuited for NCCN unfavorable intermediate-risk prostate cancer patients;Urologic Oncology: Seminars and Original Investigations;2023-11

2. Role of Chronic Inflammation as a Predictor of Upstaging/Upgrading in Prostate Cancer: Finding A New Group Eligible for Active Surveillance;UROL J;2020

3. Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study;European Urology;2020-05

4. Changes in prostate‐specific antigen at the time of prostate cancer diagnosis after Medicaid expansion in young men;Cancer;2020-04-28

5. Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer;Journal of Cancer Research and Clinical Oncology;2020-01-08